ATAI Life Sciences N.V., trading on NASDAQ under the symbol ATAI, is a clinical-stage biotechnology company. It focuses on developing psychedelic-derived therapies for mental health disorders. A key competitor in this space is Compass Pathways, which also explores psychedelic treatments. ATAI's innovative approach aims to address unmet needs in mental health, particularly treatment-resistant depression (TRD).
On March 6, 2026, Andrew Tsai from Jefferies set a price target of $10 for ATAI, while the stock was trading at $3.39. This target reflects a significant potential upside of approximately 194%. Jefferies reiterated a Buy rating, showing confidence in ATAI's promising BPL-003 Phase IIb TRD results, as highlighted by StreetInsider.
ATAI's BPL-003, an intranasal psychedelic-derived therapy, recently received FDA approval to proceed with Phase 3 clinical trials. This approval is crucial as it targets treatment-resistant depression, a condition affecting millions who do not respond to standard antidepressants. The FDA's support follows a successful end-of-phase 2 meeting, providing constructive feedback on the study design and safety requirements.
The current stock price of ATAI is $3.39, reflecting a decrease of 4.24% with a change of $0.15. Today, the stock fluctuated between a low of $3.38 and a high of $3.57. Over the past year, ATAI has seen a high of $6.75 and a low of $1.15, with a market capitalization of approximately $639.4 million.
Today's trading volume for ATAI is 7,272,515 shares on the NASDAQ exchange. This high volume indicates strong investor interest, likely driven by the recent FDA approval and Jefferies' positive outlook. As ATAI progresses with its clinical trials, investor attention remains focused on its potential to revolutionize treatment for TRD.
